Quince Therapeutics (QNCX) Stock Price, News & Analysis

Company Overview

Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.

Key Stats

• Today's Range: $1.58 to $1.62
• 50-Day Range: $1.54 to $1.90
• 52-Week Range: $0.69 to $2.45
• Volume: 132,719 shs
• Average Volume: 118,294 shs
• Market Capitalization: $85.94 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $8.14
• Consensus Rating: Buy

Quince Therapeutics Stock Analysis - MarketRank™

Quince Therapeutics scored higher than 75% of companies evaluated by MarketBeat, and ranked 285th out of 958 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.6 / 5
• Analyst Rating: Buy

Consensus Rating

Quince Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.18, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.

Upside Potential

Quince Therapeutics has a consensus price target of $8.14, representing about 408.9% upside from its current price of $1.60.

Amount of Analyst Coverage

Quince Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Quince Therapeutics are expected to grow in the coming year, from ($1.21) to ($0.79) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Quince Therapeutics is -1.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Quince Therapeutics is -1.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Quince Therapeutics has a P/B Ratio of 2.32. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.18% of the float of Quince Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Quince Therapeutics has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Quince Therapeutics has recently decreased by 3.68%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Quince Therapeutics does not currently pay a dividend.

Dividend Growth

Quince Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.18% of the float of Quince Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Quince Therapeutics has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Quince Therapeutics has recently decreased by 3.68%, indicating that investor sentiment is improving.

News and Social Media

• Score: 3.2 / 5
• News Sentiment: 0.73

News Sentiment

Quince Therapeutics has a news sentiment score of 0.73. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.92 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Quince Therapeutics this week, compared to 1 article on an average week.

Search Interest

6 people have searched for QNCX on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.

MarketBeat Follows

11 people have added Quince Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 38% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Quince Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

20.30% of the stock of Quince Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 30.75% of the stock of Quince Therapeutics is held by institutions.

QNCX Stock Analysis - Frequently Asked Questions

How have QNCX shares performed this year?

Quince Therapeutics' stock was trading at $1.87 at the start of the year. Since then, QNCX shares have decreased by 14.4% and is now trading at $1.60.

How were Quince Therapeutics' earnings last quarter?

Quince Therapeutics, Inc. (NASDAQ:QNCX) posted its quarterly earnings data on Monday, August, 11th. The company reported ($0.34) earnings per share for the quarter, missing analysts' consensus estimates of ($0.28) by $0.06.

Who are Quince Therapeutics' major shareholders?

Top institutional shareholders of Quince Therapeutics include Nantahala Capital Management LLC (4.71%), Rockefeller Capital Management L.P. (0.32%), Shay Capital LLC (0.28%) and Bridgeway Capital Management LLC (0.24%). Insiders that own company stock include Dirk Thye, Brendan Hannah, Charles S Ryan and Ted Monohon.
View institutional ownership trends.

How do I buy shares of Quince Therapeutics?

Shares of QNCX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Quince Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Quince Therapeutics investors own include Athenex (ATNX), PayPal (PYPL), SoFi Technologies (SOFI), TherapeuticsMD (TXMD), Achilles Therapeutics (ACHL), Agile Therapeutics (AGRX) and Aytu BioPharma (AYTU).

Company Calendar

• Last Earnings: 8/11/2025
• Today: 9/13/2025
• Next Earnings (Estimated): 11/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:QNCX
• CIK: 1662774
• Web: www.quincetx.com
• Phone: (650) 910-5717
• Fax: N/A
• Employees: 60
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Quince Therapeutics: $8.14
• High Price Target: $11.00
• Low Price Target: $4.00
• Potential Upside/Downside: +408.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.18
• Research Coverage: 11 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.09)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$56.83 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -187.49%
• Return on Assets: -42.47%

Debt

• Debt-to-Equity Ratio: 1.45
• Current Ratio: 5.00
• Quick Ratio: 5.00

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.69 per share
• Price / Book: 2.32

Miscellaneous

• Outstanding Shares: 53,710,000
• Free Float: 42,810,000
• Market Cap: $85.94 million
• Optionable: Optionable
• Beta: 0.99